Federated Hermes’s Meridian Bioscience Inc VIVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-430
Closed -$14.3K 2324
2022
Q4
$14.3K Buy
430
+125
+41% +$4.03K ﹤0.01% 1832
2022
Q3
$10K Buy
305
+108
+55% +$3.5K ﹤0.01% 1838
2022
Q2
$6K Sell
197
-160
-45% -$4.33K ﹤0.01% 1889
2022
Q1
$9K Hold
357
﹤0.01% 1904
2021
Q4
$7K Sell
357
-454
-56% -$8.71K ﹤0.01% 1974
2021
Q3
$16K Sell
811
-6
-0.7% -$120 ﹤0.01% 1950
2021
Q2
$18K Sell
817
-224
-22% -$4.75K ﹤0.01% 1936
2021
Q1
$27K Buy
+1,041
New +$24.8K ﹤0.01% 1930
2020
Q3
Sell
-155
Closed -$4K 2383
2020
Q2
$4K Buy
+155
New +$2.25K ﹤0.01% 2030
2019
Q4
Sell
-18,067
Closed -$171K 2337
2019
Q3
$171K Buy
+18,067
New +$190K ﹤0.01% 1603
2019
Q1
Sell
-102
Closed -$2K 2251
2018
Q4
$2K Buy
+102
New +$1.74K ﹤0.01% 2098
2018
Q3
Sell
-489
Closed -$8K 2358
2018
Q2
$8K Buy
+489
New +$7.29K ﹤0.01% 1947
2013
Q3
Sell
-131,580
Closed -$2.83M 1787
2013
Q2
$2.83M Buy
+131,580
New +$2.84M 0.01% 757

Other funds holding VIVO

Federated Hermes's VIVO Position: Q1 2023 in Review

Federated Hermes sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 430 shares — an estimated $14.3K sold.

Federated Hermes first reported a position in VIVO in Q2 2013 and held it in 13 quarters. The position peaked at $2.83M in Q2 2013. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Federated Hermes reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Federated Hermes sold 430 Meridian Bioscience Inc shares in Q1 2023, an estimated $14.3K.
  • Federated Hermes first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 13 quarters.
  • Federated Hermes's Meridian Bioscience Inc position peaked at $2.83M in Q2 2013.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Federated Hermes's 13F filing for Q1 2023, filed 8 May 2023.